Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $18.25, for a total transaction of $59,312.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total transaction of $55,152.50.
• On Monday, January 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $15.81, for a total transaction of $51,382.50.
• On Tuesday, January 2nd, Benjamin Hohl sold 9,383 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.01, for a total transaction of $140,838.83.

Enliven Therapeutics Trading Down 5.6 %

Shares of NASDAQ ELVN traded down $1.04 during midday trading on Friday, reaching $17.59. The company had a trading volume of 196,400 shares, compared to its average volume of 157,752. The business’s 50-day simple moving average is $15.93 and its 200 day simple moving average is $13.87. The stock has a market cap of $724.71 million, a P/E ratio of -8.03 and a beta of 1.05. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $24.22.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC raised its holdings in shares of Enliven Therapeutics by 1.8% in the fourth quarter. Citadel Advisors LLC now owns 2,394,448 shares of the company’s stock worth $33,139,000 after buying an additional 42,782 shares during the last quarter. Commodore Capital LP increased its stake in shares of Enliven Therapeutics by 35.6% in the second quarter. Commodore Capital LP now owns 2,348,272 shares of the company’s stock worth $47,928,000 after acquiring an additional 616,907 shares during the period. BlackRock Inc. grew its position in Enliven Therapeutics by 4,476.0% during the second quarter. BlackRock Inc. now owns 1,546,475 shares of the company’s stock valued at $31,564,000 after buying an additional 1,512,680 shares during the period. Vanguard Group Inc. grew its position in Enliven Therapeutics by 6.9% during the fourth quarter. Vanguard Group Inc. now owns 1,230,888 shares of the company’s stock valued at $17,035,000 after buying an additional 79,071 shares during the period. Finally, State Street Corp grew its position in Enliven Therapeutics by 4,847.5% during the second quarter. State Street Corp now owns 466,251 shares of the company’s stock valued at $9,516,000 after buying an additional 456,827 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.